Drug Trial Radar · NCT07791303
Safety, Tolerability and Pharmacokinetics of Oral Ketamir-2 in Healthy Adult Subjects
Last checked: Nov 20, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
57
Actual
Start
Mar 20, 2025
Primary completion
Mar 5, 2026
Study completion Mar 5, 2026
Sponsor
- Lead sponsor
- MIRA PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Aug 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a prospective, randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and pharmacokinetics of oral Ketamir-2 in healthy adult participants. The study includes single ascending dose cohorts and multiple ascending dose cohorts.
Conditions
- Healthy Adult Participants
Interventions
Ketamir-2Drug
Ketamir-2, also referred to as Ketamir hemipamoate, was administered orally as capsules containing 50 mg or 300 mg. Participants randomized to active treatment received Ketamir-2 according to assigned dose cohort. Cohorts 1 through 4 received a single dose on Day 1. Cohorts 5 through 7 received once-daily dosing from Day 1 through Day 5. Capsules were swallowed together with a glass of water after an overnight fast.
PlaceboDrug
Placebo capsules were identical in appearance to active capsules and were administered orally according to the same number of capsules and dosing schedule as the corresponding Ketamir-2 dose cohort.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Incidence of adverse eventsTime frame: From first dose through dosing period until 7 days post last dose
- Number of Participants With Clinically Significant Clinical Laboratory AbnormalitiesTime frame: From baseline through end of study visit
- Number of Participants With Clinically Significant Vital Sign AbnormalitiesTime frame: From baseline through end of study visit
- Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities on a 12-Lead ECGTime frame: From baseline through end of study visit
- Number of Participants With Clinically Significant Physical Examination FindingsTime frame: From baseline through end of study visit
- Number of Participants With Ketamine-Related Side Effects as Assessed by the Ketamine Side Effect Tool (KSET)Time frame: From baseline through end of study visit
- Change From Baseline in Bowdle Visual Analog Scale (VAS) ScoreTime frame: From baseline through end of study visit
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hadassah Clinical Research Unit
Jerusalem, Israel
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.